Recruiting × INDUSTRY × 130-nm albumin-bound paclitaxel × Clear all Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Phase 3 Recruiting
416 enrolled
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 Recruiting
1,000 enrolled
MK-2870-010
Phase 3 Recruiting
1,200 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2 Recruiting
1,130 enrolled
TroFuse-011
Phase 3 Recruiting
1,000 enrolled
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Phase 1 Recruiting
25 enrolled
INTerpath-13
Phase 2 Recruiting
180 enrolled
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Phase 2/3 Recruiting
500 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
880 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 2 Recruiting
60 enrolled
MK-3475-01G
Phase 2 Recruiting
90 enrolled
MTAPESTRY 103
Phase 1 Recruiting
350 enrolled
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3 Recruiting
524 enrolled
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase 1/2 Recruiting
60 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Phase 2 Recruiting
105 enrolled
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Phase 2/3 Recruiting
502 enrolled
GOBLET
Phase 1/2 Recruiting
122 enrolled
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Phase 3 Recruiting
430 enrolled
TIGeR-PaC
Phase 3 Recruiting
190 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
VIRO-25
Phase 2 Recruiting
142 enrolled
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Phase 3 Recruiting
602 enrolled
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
Phase 1 Recruiting
18 enrolled
HS-10502
Phase 1 Recruiting
157 enrolled
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Phase 2 Recruiting
245 enrolled
PARC
Phase NA Recruiting
10 enrolled
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Phase 3 Recruiting
360 enrolled
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phase 1/2 Recruiting
40 enrolled
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Phase 2 Recruiting
78 enrolled
ASPIRE
Phase 2/3 Recruiting
600 enrolled
AB122 Platform Study
Phase 1 Recruiting
917 enrolled
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Phase 3 Recruiting
778 enrolled